Pamela Weiss

About

Pamela Weiss, M.D., M.S.C.E., is a Professor of Pediatrics (Rheumatology) at the Children's Hospital of Philadelphia and a Senior Scholar at the Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania. Her research focuses on pharmacoepidemiology and outcomes research in pediatric juvenile idiopathic arthritis (JIA) and juvenile spondyloarthritis. She has advanced training in clinical epidemiology and biostatistics through the University of Pennsylvania School of Medicine Center for Clinical Epidemiology and Biostatistics master’s degree program. Her research aims include improving the diagnosis of pediatric spondyloarthritis, which encompasses enthesitis-related arthritis and psoriatic arthritis, better defining disease activity in children with spondyloarthritis, and developing treatment strategies that enhance both clinical and patient-reported outcomes.

Research topics

• Computer Science
• Nanotechnology
• Materials science
• Engineering

Selected publications

• Nocturnal blood pressure dipping as a marker of endothelial function and subclinical atherosclerosis in pediatric-onset systemic lupus erythematosus

  Arthritis Research & Therapy · 2020-06-03 · 27 citations

  articleOpen access

  BACKGROUND: Loss of the normal nocturnal decline in blood pressure (BP), known as non-dipping, is a potential measure of cardiovascular risk identified by ambulatory blood pressure monitoring (ABPM). We sought to determine whether non-dipping is a useful marker of abnormal vascular function and subclinical atherosclerosis in pediatric-onset systemic lupus erythematosus (pSLE). METHODS: Twenty subjects 9-19 years of age with pSLE underwent ABPM, peripheral endothelial function testing, carotid-fe…

  PublisherOA PDFDOI

• 25 Years of Biologics for the Treatment of Pediatric Rheumatic Disease: Advances in Prognosis and Ongoing Challenges

  Arthritis Care & Research · 2024-12-09 · 12 citations

  reviewOpen access

  There are over 100 rheumatic diseases and approximately 300,000 children with a pediatric rheumatic disease (PRD) in the United States. The most common PRDs are juvenile idiopathic arthritis (JIA), childhood-onset systemic lupus erythematosus (cSLE), and juvenile dermatomyositis (JDM). Effective and safe medications are essential because there are generally no cures for these conditions. Etanercept was the first biologic therapy for the treatment of JIA, approved in 1999. Since then, other biolo…

  PublisherOA PDFDOI

• Physician's global assessment of disease activity in juvenile idiopathic arthritis: consensus-based recommendations from an international task force

  Annals of the Rheumatic Diseases · 2025-02-17 · 8 citations

  articleOpen access
  PublisherOA PDFDOI

• Unmet Needs in Spondyloarthritis: Pathogenesis, Clinical Trial Design, and Nonpharmacologic Therapy

  The Journal of Rheumatology · 2024-10-24 · 3 citations

  reviewOpen accessSenior author

  A program focused on pathogenesis, clinical trial design, and nonpharmacologic mind-body therapy for spondyloarthritis (SpA) was presented at the Spondylitis Association of America Unmet Needs Conference IV. SpA pathogenesis is incompletely understood but involves a complex set of drivers, including genetics, biomechanical stress, and microbial factors. Affected tissues may include axial and peripheral joints, entheses, skin, uvea, and intestines. The specific role of key cytokines like interleu…

  PublisherOA PDFDOI

• Core Set of Responsive and Discriminatory Measures for Use in Pragmatic Trials of Youth With Axial Juvenile Spondyloarthritis

  Arthritis Care & Research · 2025-05-02 · 2 citations

  articleOpen accessSenior authorCorresponding

  OBJECTIVE: The objective of this study was to determine a core set of measures for youth with juvenile spondyloarthritis and axial disease (axJSpA), using the juvenile arthritis working group Outcome Measures in Rheumatology framework. METHODS: This was a prospective multicenter study of youth with axJSpA. Participants (aged 8-18 years) all initiated tumor necrosis factor inhibitor (TNFi) therapy and completed questionnaires, examinations, and magnetic resonance imaging (MRI) at baseline and 12…

  PublisherDOI

Recent grants

• Refining entry criteria and outcome measures for children with axial disease and spondyloarthritis: preparation for clinical trials

  NIH · $678k · 2019–2024

• NIH Grant R03AR062665

  NIH · $220k · 2016

• NIH Grant F32DK077400

  NIH · $88k · 2008

Frequent coauthors

• Rui Xiao

  Nanchang University

  153 shared

• Timothy G. Brandon

  Children's Hospital of Philadelphia

  121 shared

• R. Lambert

  University of Alberta

  113 shared

• Joyce C. Chang

  Children's Hospital of Philadelphia

  112 shared

• Walter P. Maksymowych

  109 shared

• Nancy A. Chauvin

  Cleveland Clinic

  102 shared

• David M. Biko

  Children's Hospital of Philadelphia

  99 shared

• Jacob L. Jaremko

  University of Alberta

  92 shared

Labs

• Pamela Weiss LaboratoryPI

Education

• M.S.C.E., Center for Clinical Epidemiology and Biostatistics

  University of Pennsylvania

  2009

• M.D.

  Yeshiva University Albert Einstein College of Medicine

  2002

• A.B.

  Princeton University

  1998

Awards & honors

• Senior Scholar, Center for Clinical Epidemiology and Biostat…

Similar researchers at University of Pennsylvania

• John Q. Trojanowskih-296
• Craig B. Thompsonh-277
• Daniel J Raderh-236